<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), the likelihood of having a sustained response to <z:chebi fb="0" ids="2038">azacitidine</z:chebi> is increased by maximizing treatment duration </plain></SENT>
<SENT sid="1" pm="."><plain>This is important as prognosis postrelapse is poor </plain></SENT>
<SENT sid="2" pm="."><plain>There is also the concern that early termination of treatment may result in rapid disease progression </plain></SENT>
<SENT sid="3" pm="."><plain>We reviewed outcomes in 13 patients who discontinued <z:chebi fb="0" ids="2038">azacitidine</z:chebi> (<z:chebi fb="0" ids="50131">decitabine</z:chebi> in one patient) while still responding to the treatment </plain></SENT>
<SENT sid="4" pm="."><plain>Most patients rapidly relapsed; median time to progression was 5.4Â months </plain></SENT>
<SENT sid="5" pm="."><plain>Reasons for treatment discontinuation included comorbidities, <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, and patient choice </plain></SENT>
<SENT sid="6" pm="."><plain>These findings illustrate the risk of prematurely terminating <z:chebi fb="0" ids="2038">azacitidine</z:chebi> therapy in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>